Common Cardiac Side Effects of Sprycel
Sprycel (dasatinib), a tyrosine kinase inhibitor for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), carries risks of several cardiac issues. The most frequently reported include QT prolongation, which can lead to irregular heart rhythms, and fluid retention that may cause pericardial effusion (fluid around the heart).[1][2] Clinical trials showed QT interval prolongation in about 4% of patients, with rare cases exceeding 500 msec.[1]
How Often Do These Occur?
In pooled safety data from trials:
- Pericardial effusion: Up to 10% overall, severe in 2%.[1]
- QT prolongation: 2-4% mild to moderate, <1% severe.[1]
- Myocardial ischemia or infarction: 1-3%.[1]
- Heart failure or pulmonary hypertension: Less common, around 1-2%.[1][2]
Incidence rises with longer use; monitoring is required every 1-3 months initially.[2]
Serious Risks Like Pulmonary Hypertension
Sprycel uniquely links to pulmonary arterial hypertension (PAH), a progressive condition narrowing lung arteries and straining the right heart. PAH occurred in 1-5% of patients in post-marketing reports, sometimes reversing after discontinuation. The FDA added a black box warning for this in 2011.[2][3] Symptoms include shortness of breath, fatigue, and chest pain—prompt evaluation is critical.
Why Does Sprycel Affect the Heart?
It inhibits multiple kinases, including those in cardiac ion channels and vascular cells, disrupting electrical signaling (QT changes) and causing inflammation or fluid buildup. Pre-existing heart conditions, hypertension, or concurrent QT-prolonging drugs (e.g., certain antibiotics) increase risk.[1][2]
Monitoring and Management
Baseline ECG and echocardiogram are recommended before starting, with follow-ups for symptoms like palpitations or edema. Dose reduction or switching to alternatives like imatinib may help. Avoid in patients with long QT syndrome or uncontrolled heart failure.[1][2]
Comparisons to Other TKIs
Sprycel has higher pulmonary hypertension risk than imatinib (negligible PAH) but similar QT issues to nilotinib. Bosutinib shows fewer cardiac events overall.[4] Real-world data confirm Sprycel's profile is manageable with monitoring.[1]
[1]: Sprycel Prescribing Information, Bristol-Myers Squibb, 2023. https://packageinserts.bms.com/pi/pisprycel.pdf
[2]: FDA Label for Dasatinib, 2023. https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/021986s047lbl.pdf
[3]: EMA Summary of Product Characteristics for Sprycel. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf
[4]: Lancet Haematology review on TKI cardiac safety, 2020. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30123-4/fulltext